Company press releases and official corporate announcements.
A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.
23,573 total articles
Callan JMB Inc. announced its role as an independent infrastructure and oversight partner in a collaboration to support U.S.-based manufacturing scale-up of Biostax Corp's multi-indication immune restoration platform, JKB-122 (Lodonal™). The collaboration advances the platform toward Phase 2b/3 clinical development, ensuring compliance and readines…
20/20 BioLabs, Inc. has received over $520,000 in funding from the Maryland Department of Health to provide its patented OneTest™ multi-cancer early detection blood test to more than 1,400 firefighters across 18 Maryland fire departments. This represents a significant increase in screenings compared to the prior year and reflects growing public sec…
Hudson Technologies has signed a licensing agreement with Solstice Advanced Materials to reclaim and resell patented HFO refrigerants R-448A and R-449A in the U.S. and Canada. This move enhances Hudson's presence in the commercial refrigeration market amidst regulatory phase-downs of higher GWP refrigerants, aligning with efforts to provide sustain…
Jyong Biotech Ltd., listed on Nasdaq as MENS, announced updates on its plant-derived drug candidate MCS®-2, emphasizing its clinical advantages in treating benign prostatic hyperplasia (BPH) and lower urinary tract symptoms (LUTS). The drug has completed multiple Phase III trials in the US and Taiwan with strong safety and efficacy profiles, and ho…
One and One Green Technologies. INC (NASDAQ: YDDL), a licensed hazardous waste recycler in the Philippines, announced a new business venture to recover copper-gold ore tailings slag in Luzon. This strategic initiative targets the projected global copper supply deficit of 150,000 metric tons in 2026 by partnering with local small-scale miners and le…
ORIC Pharmaceuticals announced plans to report combination dose optimization data from its Phase 1b trial of rinzimetostat in metastatic castration resistant prostate cancer patients. The presentation will occur during a webcast and conference call on March 31, 2026. This update provides insights into dosing strategies for an investigational allost…
BranchOut Food Inc., a food technology company specializing in natural fruit and vegetable snacks using its proprietary GentleDry process, announced a conference call to discuss its Q4 and full-year 2025 financial results along with a corporate and shareholder update scheduled for March 31, 2026. The company highlighted its patented dehydration tec…
Ocean Power Technologies announced securing a contract to deliver a fully integrated WAM-V autonomous surface vehicle to a new underwater research customer in the Nordics. This order marks an expansion of the company's presence in the Nordic region and demonstrates ongoing demand across multiple sectors including defense, surface inspections, and u…
Cyabra, a company dedicated to identifying coordinated manipulation in online narratives and protecting digital trust, has completed its business combination with Trailblazer Merger Corp. Cyabra's common stock is set to begin trading on Nasdaq on March 27, 2026, under the ticker CYAB. The combination supports Cyabra's mission to combat disinformati…
Quantum BioPharma Ltd. announced its audited financial results for 2025 showing a strong balance sheet with $11.3 million in cash and digital assets, improved working capital, and reduced operating expenses. The company completed Phase 1 toxicology studies for its oral MS drug candidate Lucid-MS, advancing toward Phase 2 trials. Additionally, clini…
Inflection Point Acquisition Corp. VI, a special purpose acquisition company (SPAC), announced the pricing of its IPO, offering 22 million units at $10 each, expected to raise $220 million. The units will trade on Nasdaq under ticker IPFXU, with separate trading expected for shares and warrants under IPFX and IPFXW respectively. The company aims to…
Hydrofarm Holdings Group, Inc. announced its fourth quarter and full year 2025 financial results showing a 32.7% reduction in net sales for Q4 compared to the prior year, driven by industry oversupply and price decreases. Despite improvements in gross profit margins and reduced operating expenses due to restructuring efforts, the company reported a…
Glucotrack, Inc. announced significant progress towards filing an Investigational Device Exemption (IDE) with the U.S. FDA in Q2 2026 to initiate a U.S. clinical trial for its implantable continuous blood glucose monitoring system. Following successful first-in-human trials in Brazil and a follow-up study in Australia, the company completed key tri…
Senti Biosciences announced its fourth quarter and full year 2025 financial results, marking significant progress in its clinical pipeline, particularly with SENTI-202 for relapsed/refractory acute myeloid leukemia (AML). The company reported positive preliminary Phase 1 clinical data, received FDA Regenerative Medicine Advanced Therapy designation…
Norwegian Cruise Line Holdings Ltd. announced the appointment of John W. Chidsey as President and CEO, effective February 2026, accompanied by a new employment agreement and a $48 million restricted share unit award designed to incentivize long-term shareholder value creation over four years. The equity award includes performance-based and time-ves…
Profound Medical Corp. announced that Texas Prostate, led by Dr. James Cochran, has reached the milestone of performing 100 TULSA Procedures using Profound's TULSA-PRO system at Dallas Medical Center. The collaboration has increased procedure volume by 500% since transitioning to a Medicare payment model, accelerating adoption of this innovative, M…
Clearmind Medicine Inc., a Nasdaq-listed clinical-stage biotech company, announced the filing of a patent application in India for next-generation psychedelic compounds aimed at treating mental health disorders and addiction. This move expands the company's global intellectual property portfolio and builds on its licensing agreement with Yissum Res…
Streamex Corp. clarifies and disproves misleading third-party reports about the expiration of lock-up agreements related to its January 2026 financing. The company confirms that the previous lock-ups of certain shares held by co-founders Henry McPhie and Morgan Lekstrom were shorter than reported and that newly agreed voluntary one-year lock-ups ha…
Sportradar Group AG, a leading global sports technology company, announced the filing of its annual report on Form 20-F for the fiscal year ended December 31, 2025, with the SEC. The report is available to investors via the company’s website and SEC filings. Sportradar provides technology and services to sports federations, media, and betting opera…
SFL Corporation Ltd., a maritime shipping company listed on the NYSE, announced its Annual General Meeting to be held on May 11, 2026, with voting record date set for April 1, 2026. The company highlighted its stable dividend record since 2004 and provided a cautionary statement about risks and uncertainties affecting its business including market …
ParaZero Technologies Ltd. announced a successful transformation in 2025 from a drone safety components supplier to a leading Tier 1 defense provider specializing in multi-layered autonomous counter-unmanned aerial systems (C-UAS). The company reported a 12% year-over-year revenue growth in 2025, with early 2026 orders already exceeding the full pr…
Aurora Mobile has entered into a strategic partnership with Soochow Securities to integrate its intelligent push notification platform, JPush, into Soochow Securities' 'Dongwu Xiucai' mobile app. This collaboration aims to improve real-time, secure delivery of financial notifications and personalized client communication, advancing Soochow's digita…
Satellos Bioscience Inc. reported significant progress in 2025, including closing a $57.2 million equity financing, commencing Nasdaq trading under ticker MSLE, and initiating two Phase 2 clinical trials (BASECAMP and TRAILHEAD) for its lead candidate SAT-3247 targeting Duchenne muscular dystrophy (DMD). Clinical data showed maintained or improved …
Legence Corp. reported record quarterly revenues of $737.6 million for Q4 2025, a 34.6% increase year-over-year, driven mainly by organic growth. The company posted a 53% increase in quarterly Adjusted EBITDA and a 49% increase in total backlog and awarded contracts to $3.7 billion. Strategic acquisitions including Bowers and Metrix enhance its mar…
Autolus Therapeutics reported fourth quarter and full year 2025 financial results highlighted by $74.3 million in net product revenue for their CAR T cell therapy AUCATZYL, approved for relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL). The company has launched AUCATZYL in the UK following positive NICE evaluation and expects conti…
